Access to therapy is part of the protection of the constitutional order: Peter Bely spoke at the SPIEF session on intellectual property
23.09.2020
Medicines
23.09.2020
According to the Promomed company, this affected the cost of the medicine for the consumer.
MOSCOW, September 23. /tass/. The volume of investments in the development of the coronavirus drug Areplivir, which is now allowed to be used on an outpatient basis, amounted to more than 692 million rubles, and this affected the cost of the drug for consumers. This was announced by Andrey Mladentsev, Executive Director of Promomed, during an online conference.
Previously the head of Promomed TASS reported that the packaging of the drug "Areplivir" It will cost from 12,320 rubles at retail. One package contains 40 tablets of 200 mg each.
"The total investment in the development and creation of the drug, including the creation of a special production facility, the development of technology for the synthesis of the substance, amounted to more than 692 million rubles. Of course, this puts a heavy burden on the price of the drug," Infants said at the conference, noting that the company had not received government funding and investments were made from its own funds.
According to him, the price of the medicine is "a big headache for the company." "We are currently working purposefully in order to increase production efficiency. With increasing volumes, we hope that the price of the drug will be able to decrease," said the head of Promomed. At the same time, he recalled that the treatment of coronavirus infection in a hospital, depending on the region, costs from 20 thousand rubles. per day.
He also expressed the hope that the drug will be included in the list of vital medicines (VED), a maximum selling price will be set for it and it will be included in the compulsory health insurance program. "Then insurance medicine can cover the costs of providing medicines," explained Infants.
Peter Bely, Chairman of the Board of Directors of Promomed Group, noted that the company had to build a separate isolated production facility to create the drug. "In fact, it is a factory within a factory in order to produce this substance. These are investments that have allowed us to create a technology whose scaling creates opportunities to improve the cost of a product. And we hope that this will happen in the very near future or when it is technologically possible," he concluded.
Source: tass.ru
Sources
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office
